Continuum of hepatitis C care in France: A 20-year cohort study.

about

Continuum of hepatitis C care in France: A 20-year cohort study.

Item

http://www.wikidata.org/entity/Q40066639

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Continuum of hepatitis C care in France: A 20-year cohort study.

@en

type

Item

label

Continuum of hepatitis C care in France: A 20-year cohort study.

@en

prefLabel

Continuum of hepatitis C care in France: A 20-year cohort study.

@en

P1476

Continuum of hepatitis C care in France: A 20-year cohort study.

@en

P2093

Bernard Royer

http://www.w3.org/2001/XMLSchema#string

Catherine Gaudy-Graffin

http://www.w3.org/2001/XMLSchema#string

Christophe Gaborit

http://www.w3.org/2001/XMLSchema#string

Coralie Hermetet

http://www.w3.org/2001/XMLSchema#string

Frederic Dubois

http://www.w3.org/2001/XMLSchema#string

Leslie Grammatico-Guillon

http://www.w3.org/2001/XMLSchema#string

Louis D'Alteroche

http://www.w3.org/2001/XMLSchema#string

Philippe Roingeard

http://www.w3.org/2001/XMLSchema#string

Yannick Bacq

http://www.w3.org/2001/XMLSchema#string

P2860

Changing the face of hepatitis C management - the design and development of sofosbuvir

Usefulness of the Hepatitis C Virus Core Antigen Assay for Screening of a Population Undergoing Routine Medical Checkup

The natural history of hepatitis C virus (HCV) infection.

Global epidemiology of hepatitis C virus infection

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses.

Treatment of hepatitis C. The 2002 French consensus.

Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment.

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

P304

e0183232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0183232

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Catherine Gaudy-Graffin

Jean-Claude Desenclos

P577

2017-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28850623

http://www.w3.org/2001/XMLSchema#string

P932

5574535

http://www.w3.org/2001/XMLSchema#string